Jonathan Goldman's most recent trade in Avalo Therapeutics Inc was a trade of 8,200 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 8,200 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Sale of securities on an exchange or to another person at price $ 14.35 per share. | 14 Nov 2025 | 8,200 | 0 | - | 14.3 | 117,649 | Common Stock |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. | 14 Nov 2025 | 8,200 | 8,200 | - | 9.9 | 81,016 | Common Stock |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Sale of securities on an exchange or to another person at price $ 14.30 per share. | 14 Nov 2025 | 3,167 | 0 | - | 14.3 | 45,288 | Common Stock |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Jonathan Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units |